Ann: USA Sales Update, page-31

I’m surprised the price is still so low after such a bullish announcement. Guessing the institutional traders/investors must still be getting adjusted to life back at the office after a decent break. These are the hard numbers that prove iTrack Advance is indeed a best in class treatment that will grow rapidly in sales and become a gold standard of treatment for Glaucoma. If they could get 65% growth even with everything that was going on towards the end of last year, well that’s a pretty amazing accomplishment. Very surprised that the market is still clearly asleep with this one.